LRRC10

Summary

LRRC10 (leucine rich repeat containing 10, HGNC:20264) is a protein-coding gene on chromosome 12q15, encoding Leucine-rich repeat-containing protein 10 (Q5BKY1). May play important roles in cardiac development and/or cardiac function.

Predicted to enable actin binding activity. Predicted to be involved in cardiac muscle cell development. Predicted to be located in mitochondrion; myofibril; and nucleus. Predicted to be active in cytoskeleton and sarcomere.

Source: NCBI Gene 376132 — RefSeq curated summary.

At a glance

• Gene–disease (curated): dilated cardiomyopathy (No Known Disease Relationship, ClinGen)
• GWAS associations: 4
• Clinical variants (ClinVar): 211 total
• MANE Select transcript: NM_201550

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20264
Approved symbol	LRRC10
Name	leucine rich repeat containing 10
Location	12q15
Locus type	gene with protein product
Status	Approved
Aliases	HRLRRP, LRRC10A
Ensembl gene	ENSG00000198812
Ensembl biotype	protein_coding
OMIM	610846
Entrez	376132

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000361484

RefSeq mRNA: 1 — MANE Select: NM_201550 NM_201550

CCDS: CCDS31856

Canonical transcript exons

ENST00000361484 — 1 exons

Exon	Start	End
ENSE00001434811	69608564	69610907

Expression profiles

Bgee: expression breadth broad, 13 present calls, max score 91.93.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1325 / max 112.4346, expressed in 17 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
132026	0.1215	17
132023	0.0109	2

Top tissues by expression

122 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	91.93	gold quality
heart left ventricle	UBERON:0002084	86.73	gold quality
right atrium auricular region	UBERON:0006631	80.37	gold quality
heart	UBERON:0000948	78.41	gold quality
lymph node	UBERON:0000029	46.38	gold quality
granulocyte	CL:0000094	43.09	silver quality
sural nerve	UBERON:0015488	40.56	gold quality
vermiform appendix	UBERON:0001154	40.27	gold quality
gastrocnemius	UBERON:0001388	40.23	silver quality
muscle of leg	UBERON:0001383	39.45	silver quality
gall bladder	UBERON:0002110	38.01	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
bone marrow	UBERON:0002371	36.39	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
muscle tissue	UBERON:0002385	35.68	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
leukocyte	CL:0000738	34.91	gold quality
skeletal muscle tissue	UBERON:0001134	34.89	gold quality
monocyte	CL:0000576	34.25	gold quality
cerebellar hemisphere	UBERON:0002245	33.20	gold quality
cerebellum	UBERON:0002037	33.07	gold quality
placenta	UBERON:0001987	33.04	silver quality
cerebellar cortex	UBERON:0002129	33.02	gold quality
smooth muscle tissue	UBERON:0001135	32.78	gold quality
liver	UBERON:0002107	32.47	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
right hemisphere of cerebellum	UBERON:0014890	32.11	gold quality
tonsil	UBERON:0002372	31.86	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.81

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA4, MEF2C, NKX2-5

miRNA regulators (miRDB)

61 targeting LRRC10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-370-5P	99.78	66.81	706
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-5003-5P	99.61	69.13	1624
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-5584-5P	99.49	68.22	2814

Literature-anchored findings (GeneRIF, showing 4)

• This study firstly reports the association of LRRC10 mutations with enhanced susceptibility to dilated cardiomyopathy in humans. (PMID:26017719)
• LRRC10 may be a new susceptible gene for Sudden unexplained nocturnal death syndrome, and LRRC10 variant was initially and genetically linked to Brugada syndrome associated arrhythmia. (PMID:28032242)
• Examination of a patient with dilated cardiomyopathy revealed homozygosity for a previously unreported LRRC10 variant: I195T. Wild-type and I195T LRRC10 function as cardiac-specific subunits of L-type Ca(2+) channels and exert dramatically different effects on channel gating, providing a potential link to DCM. (PMID:29431102)
• Cardiac L-type calcium channel regulation by Leucine-Rich Repeat-Containing Protein 10. (PMID:38762910)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	lrrc10	ENSDARG00000045612
mus_musculus	Lrrc10	ENSMUSG00000060187

Paralogs (31): LRRC7 (ENSG00000033122), PHLPP2 (ENSG00000040199), LRRC40 (ENSG00000066557), LRCH4 (ENSG00000077454), PHLPP1 (ENSG00000081913), SHOC2 (ENSG00000108061), ERBIN (ENSG00000112851), LRRC39 (ENSG00000122477), LRCH2 (ENSG00000130224), LRCH1 (ENSG00000136141), LRRC8A (ENSG00000136802), LRRC1 (ENSG00000137269), MFHAS1 (ENSG00000147324), LRRC27 (ENSG00000148814), LRRK1 (ENSG00000154237), LRRC58 (ENSG00000163428), LRRC2 (ENSG00000163827), LRRC18 (ENSG00000165383), LRRC28 (ENSG00000168904), LRRC8E (ENSG00000171017), LRRC8C (ENSG00000171488), LRRC8D (ENSG00000171492), PIDD1 (ENSG00000177595), SCRIB (ENSG00000180900), LRCH3 (ENSG00000186001), LRRIQ4 (ENSG00000188306), LRRC8B (ENSG00000197147), LRRC10B (ENSG00000204950), LRRC30 (ENSG00000206422), LRRC69 (ENSG00000214954), LRRD1 (ENSG00000240720)

Protein

Protein identifiers

Leucine-rich repeat-containing protein 10 — Q5BKY1 (reviewed: Q5BKY1)

All UniProt accessions (1): Q5BKY1

UniProt curated annotations — full annotation on UniProt →

Function. May play important roles in cardiac development and/or cardiac function.

Subcellular location. Nucleus.

RefSeq proteins (1): NP_963844* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050216	LRR_domain-containing	Family

Pfam: PF13855

UniProt features (8 total): repeat 7, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5BKY1-F1	86.54	0.75

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 34 (showing top): GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_CARDIAC_MUSCLE_CELL_DIFFERENTIATION, NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON, GOBP_CARDIOCYTE_DIFFERENTIATION, GOMF_ACTIN_BINDING, GOBP_MUSCLE_CELL_DEVELOPMENT, GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT, GOBP_CARDIAC_CELL_DEVELOPMENT, GOBP_MUSCLE_CELL_DIFFERENTIATION, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOMF_ACTININ_BINDING, GOMF_CYTOSKELETAL_PROTEIN_BINDING, GOMF_ALPHA_ACTININ_BINDING

GO Biological Process (1): cardiac muscle cell development (GO:0055013)

GO Molecular Function (3): actin binding (GO:0003779), alpha-actinin binding (GO:0051393), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), mitochondrion (GO:0005739), cytoskeleton (GO:0005856), sarcomere (GO:0030017), myofibril (GO:0030016)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
striated muscle cell development	1
cardiac cell development	1
cardiac muscle cell differentiation	1
cytoskeletal protein binding	1
actinin binding	1
binding	1
cytoplasm	1
intracellular membraneless organelle	1
myofibril	1
cellular anatomical structure	1
contractile muscle fiber	1

Protein interactions and networks

STRING

962 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRC10	BEST3	Q8N1M1	550
LRRC10	CCT2	P78371	544
LRRC10	SLMAP	Q14BN4	498
LRRC10	FRS2	Q8WU20	495
LRRC10	RANGRF	Q9HD47	480
LRRC10	KCNE5	Q9UJ90	475
LRRC10	TSPAN31	Q12999	468
LRRC10	HTR4	Q13639	462
LRRC10	ATP23	Q9Y6H3	458
LRRC10	LRRC52	Q8N7C0	448
LRRC10	LRRC26	Q2I0M4	447
LRRC10	METTL1	Q9UBP6	436
LRRC10	LRRC38	Q5VT99	431
LRRC10	GPD1L	Q8N335	430
LRRC10	BBS10	Q8TAM1	428

IntAct

6 interactions, top by confidence:

A	B	Type	Score
LRRC10	CCT2	psi-mi:“MI:0914”(association)	0.530
LRRC10		psi-mi:“MI:0915”(physical association)	0.400
LRRC10	A2ML1	psi-mi:“MI:0914”(association)	0.350
TBXA2R	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
LRRC10	TUSC2	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): LRRC10 (Synthetic Lethality), ENOSF1 (Affinity Capture-MS), CCT6B (Affinity Capture-MS), SUGT1 (Affinity Capture-MS), ARHGAP8 (Affinity Capture-MS), CCT2 (Affinity Capture-MS), LRRC10 (Affinity Capture-MS), LRRC10 (Proximity Label-MS), EVPL (Affinity Capture-MS), IGHG1 (Affinity Capture-MS), LCN2 (Affinity Capture-MS), FLG (Affinity Capture-MS), CCT6B (Affinity Capture-MS), IGKC (Affinity Capture-MS), POF1B (Affinity Capture-MS)

ESM2 similar proteins: A0JM56, A0JPI9, A4IHG1, A5PK13, D3YY91, F1ND48, O35125, Q13309, Q15813, Q24K06, Q32KP2, Q32KS0, Q32L08, Q32NT4, Q3KQF4, Q3KRC6, Q3UGP9, Q498T9, Q4U2V3, Q5BKY1, Q5DU41, Q5FVQ9, Q5PQJ7, Q5QJ74, Q5R8X9, Q5RBD9, Q5U378, Q66JT1, Q68F79, Q6GQN5, Q6NSJ5, Q6NU09, Q6P9F7, Q6WRX3, Q6ZNQ3, Q8C5W3, Q8CDN9, Q8CIV8, Q8IY45, Q8IZ02

Diamond homologs: A6NIK2, Q24K06, Q5BKY1, Q8K3W2, O74874, Q9C2R2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

211 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	143
Likely benign	52
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

10 predictions. Top by Δscore:

Variant	Effect	Δscore
12:69609028:T:G	acceptor_gain	0.5100
12:69609027:T:TG	acceptor_gain	0.5000
12:69609953:T:TA	donor_gain	0.4100
12:69610255:A:AC	donor_gain	0.3500
12:69609928:T:TA	donor_gain	0.3000
12:69609021:CAAAC:C	acceptor_gain	0.2500
12:69609026:CTTT:C	acceptor_gain	0.2500
12:69609933:T:A	donor_gain	0.2500
12:69610188:G:T	donor_gain	0.2200
12:69610334:G:C	donor_gain	0.2000

AlphaMissense

1804 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:69610156:G:T	P228H	0.996
12:69610173:A:C	N222K	0.993
12:69610173:A:T	N222K	0.993
12:69610189:A:T	V217D	0.993
12:69610234:A:G	I202T	0.991
12:69610225:A:G	F205S	0.990
12:69610239:G:C	N200K	0.989
12:69610239:G:T	N200K	0.989
12:69610294:A:G	F182S	0.989
12:69610126:C:T	G238E	0.988
12:69610184:A:C	Y219D	0.988
12:69610240:T:A	N200I	0.988
12:69610157:G:A	P228S	0.987
12:69610255:A:T	I195N	0.987
12:69610402:A:T	L146H	0.987
12:69610531:A:G	L103P	0.987
12:69610127:C:G	G238R	0.986
12:69610127:C:T	G238R	0.986
12:69610175:T:A	N222Y	0.986
12:69610600:A:G	L80P	0.986
12:69610663:A:G	L59P	0.986
12:69610126:C:A	G238V	0.985
12:69610127:C:A	G238W	0.985
12:69610175:T:C	N222D	0.985
12:69610531:A:T	L103H	0.985
12:69610669:A:G	L57P	0.985
12:69610669:A:T	L57H	0.985
12:69610318:A:G	L174P	0.984
12:69610462:A:G	L126P	0.984
12:69610471:A:T	L123H	0.984

dbSNP variants (sampled 300 via entrez): RS1002033341 (12:69609026 C>A,T), RS1002467555 (12:69608684 G>A,C,T), RS1003705541 (12:69610424 C>T), RS1003792881 (12:69608462 G>A,T), RS1003895625 (12:69608963 T>C), RS1004344001 (12:69612529 A>G), RS1004715907 (12:69612116 G>A,T), RS1005999004 (12:69610659 G>A,C), RS1006009782 (12:69611534 G>A), RS1006049803 (12:69611242 G>T), RS1006445963 (12:69611007 C>T), RS1008085518 (12:69609178 G>A), RS1008731269 (12:69609801 C>T), RS1009981266 (12:69611663 T>C), RS1010580064 (12:69608704 A>T)

Disease associations

OMIM: gene MIM:610846 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
dilated cardiomyopathy	No Known Disease Relationship	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
dilated cardiomyopathy	No Known Disease Relationship	AR

Mondo (1): dilated cardiomyopathy (MONDO:0005021)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST000175_26	Height	3.000000e-06
GCST006414_12	Atrial fibrillation	2.000000e-13
GCST006414_64	Atrial fibrillation	9.000000e-09
GCST007006_11	Logical memory (delayed recall) in normal cognition	4.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Doxorubicin	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	increases methylation, decreases methylation	1
Cadmium	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Triclosan	decreases expression	1

Clinical trials (associated diseases)

158 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT00847964	PHASE2	COMPLETED	Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01302171	PHASE2	COMPLETED	Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
NCT01350310	PHASE2	COMPLETED	Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
NCT02133911	PHASE2	COMPLETED	A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
NCT03071653	PHASE2	SUSPENDED	Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
NCT03572660	PHASE2	ACTIVE_NOT_RECRUITING	Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM
NCT03775070	PHASE2	COMPLETED	Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
NCT04405804	PHASE2	UNKNOWN	Early Administration of Ivabradine in Children With Heart Failure
NCT05410873	PHASE2	COMPLETED	Examining the Effects of Mitochondrial Oxidative Stress in DCM
NCT06632834	PHASE2	RECRUITING	Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
NCT00585546	PHASE1	TERMINATED	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT02293603	PHASE1	UNKNOWN	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
NCT03062956	PHASE1	COMPLETED	A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03129568	PHASE1	COMPLETED	Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT04982081	PHASE1	UNKNOWN	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
NCT06381466	PHASE1	TERMINATED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06464588	PHASE1	RECRUITING	A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06902896	PHASE1	COMPLETED	Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
NCT07137338	PHASE1	RECRUITING	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07241104	PHASE1	RECRUITING	A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy